<scp>COVID</scp>‐19 vaccination and alopecia areata: a case report and literature review

Ganjei, Zakiye; Panah, Mohammad Yazdan; Rahmati, Rahem; Meidani, Fatemeh Zari; Mosavi, Azam

doi:10.1002/ccr3.6039

Cited by 10 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding personal histories of alopecia areata, 52.6% (n = 10) of reports claimed that participants had a personal history of alopecia areata [ 11 , 12 , 19 , 20 , 21 ]; however, within our participants, only one woman (20%) recorded a personal history of alopecia universalis prior to the administration of COVID-19 vaccines.…”

Section: Discussionmentioning

confidence: 77%

“…As of November 1, 2022, a total of 7 reports have been published that include 19 individuals in which alopecia was associated with COVID-19 vaccines. The available resources are limited to case reports and case series that have exposed the development of alopecia areata (n = 15), alopecia totalis (n = 1), and alopecia universalis (n = 3) [ 11 , 12 , 19 , 20 , 21 , 22 , 23 ]. According to sex, the available data show that 68.4% (n = 13) corresponded to women; meanwhile, among our participants, the most cases were male.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme

Arroyo¹,

Izquierdo-Condoy

Ortíz-Prado

2023

Vaccines

View full text Add to dashboard Cite

COVID-19 vaccines have positively changed the course of the pandemic. They entered the market after only one year of the initial trials, which that yielded positive results in terms of safety and efficacy. However, after inoculating billions of people in the most extensive vaccination campaign worldwide, mild but common and some rare but potentially fatal adverse events have been reported. Among several self-reported adverse events, hair loss and alopecia have been linked to COVID-19 mRNA or viral vector vaccines. We tracked and followed a series of five cases with post-vaccine telogen effluvium and alopecia development in Ecuador. Here, we reported the clinical presentation of two women and three men with the diagnosis of post-vaccine hair loss. All patients received a heterologous vaccination scheme (mRNA and attenuated virus vaccine) with an additional viral vector booster associated with the apparition of telogen effluvium and alopecia universalis between 3 and 17 days after the vaccine was administered.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme

Arroyo¹,

Izquierdo-Condoy

Ortíz-Prado

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Wu et al 39 conducted a systematic review and reported that the majority of patients with new‐onset psoriasis presented 1 to 2 weeks (range, 2–21 days) following vaccination. Ganjei et al 40 reviewed 19 cases of alopecia areata occurrence after COVID‐19 vaccination, and 11 cases had a reported onset within 2 weeks (range, a few days to 4 months).…”

Section: Discussionmentioning

confidence: 99%

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

Tsai

2023

The Journal of Dermatology

View full text Add to dashboard Cite

Vitiligo is an autoimmune skin disorder that occurs due to immunemediated loss of functional melanocytes, leading to patchy skin depigmentation. The triggering of an autoimmune phenomena in patients infected with coronavirus disease 2019 (COVID-19) and those receiving COVID-19 vaccinations has been increasingly reported, and these adverse events have also been seen in vitiligo. Cases of new-onset and exacerbation of vitiligo following COVID-19 vaccination have been reported in individuals of all ages, ethnicities, and with different vaccine types. While current guidelines and consensus recommend COVID-19 vaccination for most patients, including those with autoimmune diseases, 1,2 practitioners must assess the risk and potential for disease onset or flare-up. According to the Taiwan Centers for Disease Control, around 21.7 million people in our population have received at least one primary COVID-19 vaccine, with 94% of them having been vaccinated, while 88% have received at least two doses and 74% have received at least three doses. In light of the emergence of new Delta and Omicron variants, booster vaccination programs are now underway to enhance the humoral response. Some eligible groups can now receive the fourth vaccination booster and a fifth booster dose of Moderna's next-generation bivalent vaccine.Our study aims to report the incidence of vitiligo following primary and booster COVID-19 vaccines. We retrospectively reviewed electronic medical records of new-onset and exacerbations of vitiligo following COVID-19 vaccinations at our vitiligo clinic, which is located at a tertiary referral center. In addition, we conducted a systematic review to analyze the current evidence regarding COVID-19 vaccine-associated vitiligo. | MATERIAL S AND ME THODSWe conducted a retrospective study at our vitiligo clinic, which is located at a Taiwanese tertiary medical center (Chang Gung Memorial Hospital, Linkou, and Taipei branches). The study included patients with new-onset vitiligo or exacerbations of preexisting vitiligo that were diagnosed within a month of receiving COVID-19 vaccination between January 1, 2021, and September 30, 2022. We clinically diagnosed vitiligo based on the presence of acquired amelanotic macules and patches with well-defined margins and typical distribution. Wood's lamp examination was used to identify vitiligo lesions

show abstract

“…Recently published reports from some parts of the world have reported the onset of AA in some individuals who received the COVID-19 vaccination [6][7][8]. Tassone and colleagues from Italy reported the occurrence of AA weeks after receiving mRNA or adenovirus COVID-19 vaccination in 24 patients [6].…”

Section: Introductionmentioning

confidence: 99%

“…Another case report from Italy reported an individual with rapid onset of AA after receiving the second dose of BNT162b2 (Pfizer) mRNA COVID-19 vaccine [7]. Furthermore, cases of AA have also been reported in Iran within two weeks of administration of AZD1222 (Oxford/AstraZeneca) COVID-19 vaccinations [8].…”

Section: Introductionmentioning

confidence: 99%

The Incidence of Alopecia Areata in a COVID-19-Vaccinated Population: A Single-Center Review

Chen,

Cano-Besquet,

Ghantarchyan

et al. 2023

Cureus

View full text Add to dashboard Cite

BackgroundCases of alopecia areata (AA) attributed to the coronavirus disease 2019 (COVID-19) vaccination have been reported in recent literature. However, these reports are reflective of specific geographic areas, and whether this phenomenon is observed in other regions remains to be investigated. This study focused on the association between AA and COVID-19 vaccination among patients from a large single-center safety net hospital in California. MethodologyIn this study, using electronic health records of patients and publicly available vaccination data, the demographics of patients including age group, sex, and race along with the vaccination status were carefully reviewed. ResultsA total of 73 cases of AA in the period from the release of the COVID-19 vaccination on December 17, 2020, to February 10, 2023, were identified. The odds ratios (ORs) for developing AA among the vaccinated and unvaccinated for each demographic level were calculated. Among all vaccinated individuals, the OR for developing AA was 0.58 (95% confidence interval (CI) = 0.35-0.94, p-value = 0.02). ConclusionsThis investigation noted no apparent increase in the incidence of AA among the vaccinated population compared to the unvaccinated population.

show abstract

COVID‐19 vaccination and alopecia areata: a case report and literature review

Cited by 10 publications

References 8 publications

A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme

A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

The Incidence of Alopecia Areata in a COVID-19-Vaccinated Population: A Single-Center Review

Contact Info

Product

Resources

About